Selected research
Market Analysis & Forecast
Global Machine Learning in Respiratory Diseases Market Analysis and Forecast 2026-2032
Market perspective
The global Machine Learning in Respiratory Diseases market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Machine Learning in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Machine Learning in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Machine Learning in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Machine Learning in Respiratory Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Machine Learning in Respiratory Diseases include ArtiQ, Philips Healthcare, GE Healthcare, Siemens Healthineers, Swaasa AI, THIRONA, DeepMind Health, Verily and VIDA Diagnostics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Machine Learning in Respiratory Diseases, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Machine Learning in Respiratory Diseases, also provides the revenue of main regions and countries. Of the upcoming market potential for Machine Learning in Respiratory Diseases, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Machine Learning in Respiratory Diseases revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Machine Learning in Respiratory Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Machine Learning in Respiratory Diseases revenue, projected growth trends, production technology, application and end-user industry.
Machine Learning in Respiratory Diseases Segment by Company
ArtiQ
Philips Healthcare
GE Healthcare
Siemens Healthineers
Swaasa AI
THIRONA
DeepMind Health
Verily
VIDA Diagnostics Inc
Icometrix
Infervision
PneumoWave
Respiray
Dectrocel Healthcare
Zynnon
Machine Learning in Respiratory Diseases Segment by Type
Pulmonary Infection
MRI
CT Scan
Machine Learning in Respiratory Diseases Segment by Application
Hospital
Diagnostic Centers
Ambulatory Surgical Centers
Others
Machine Learning in Respiratory Diseases Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Machine Learning in Respiratory Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Machine Learning in Respiratory Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Machine Learning in Respiratory Diseases.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Machine Learning in Respiratory Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Machine Learning in Respiratory Diseases company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Machine Learning in Respiratory Diseases revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pulmonary Infection
- MRI
- CT Scan
Applications
- Hospital
- Diagnostic Centers
- Ambulatory Surgical Centers
- Others
Companies covered
- ArtiQ
- Philips Healthcare
- GE Healthcare
- Siemens Healthineers
- Swaasa AI
- THIRONA
- DeepMind Health
- Verily
- VIDA Diagnostics Inc
- Icometrix
- Infervision
- PneumoWave
- Respiray
- Dectrocel Healthcare
- Zynnon
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Machine Learning in Respiratory Diseases Market by Type
- 1.2.1 Global Machine Learning in Respiratory Diseases Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Pulmonary Infection
- 1.2.3 MRI
- 1.2.4 CT Scan
- 1.3 Machine Learning in Respiratory Diseases Market by Application
- 1.3.1 Global Machine Learning in Respiratory Diseases Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Diagnostic Centers
- 1.3.4 Ambulatory Surgical Centers
- 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Machine Learning in Respiratory Diseases Market Dynamics
- 2.1 Machine Learning in Respiratory Diseases Industry Trends
- 2.2 Machine Learning in Respiratory Diseases Industry Drivers
- 2.3 Machine Learning in Respiratory Diseases Industry Opportunities and Challenges
- 2.4 Machine Learning in Respiratory Diseases Industry Restraints
3 Global Growth Perspective
- 3.1 Global Machine Learning in Respiratory Diseases Market Perspective (2021-2032)
- 3.2 Global Machine Learning in Respiratory Diseases Growth Trends by Region
- 3.2.1 Global Machine Learning in Respiratory Diseases Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Machine Learning in Respiratory Diseases Market Size by Region (2021-2026)
- 3.2.3 Global Machine Learning in Respiratory Diseases Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Machine Learning in Respiratory Diseases Revenue by Players
- 4.1.1 Global Machine Learning in Respiratory Diseases Revenue by Players (2021-2026)
- 4.1.2 Global Machine Learning in Respiratory Diseases Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Machine Learning in Respiratory Diseases Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Machine Learning in Respiratory Diseases Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Machine Learning in Respiratory Diseases Key Players Headquarters & Area Served
- 4.4 Global Machine Learning in Respiratory Diseases Players, Product Type & Application
- 4.5 Global Machine Learning in Respiratory Diseases Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Machine Learning in Respiratory Diseases Market CR5 and HHI
- 4.6.3 2025 Machine Learning in Respiratory Diseases Tier 1, Tier 2, and Tier 3
5 Machine Learning in Respiratory Diseases Market Size by Type
- 5.1 Global Machine Learning in Respiratory Diseases Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Machine Learning in Respiratory Diseases Revenue by Type (2021-2032)
- 5.3 Global Machine Learning in Respiratory Diseases Revenue Market Share by Type (2021-2032)
6 Machine Learning in Respiratory Diseases Market Size by Application
- 6.1 Global Machine Learning in Respiratory Diseases Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Machine Learning in Respiratory Diseases Revenue by Application (2021-2032)
- 6.3 Global Machine Learning in Respiratory Diseases Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 ArtiQ
- 7.1.1 ArtiQ Company Information
- 7.1.2 ArtiQ Business Overview
- 7.1.3 ArtiQ Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.1.4 ArtiQ Machine Learning in Respiratory Diseases Product Portfolio
- 7.1.5 ArtiQ Recent Developments
- 7.2 Philips Healthcare
- 7.2.1 Philips Healthcare Company Information
- 7.2.2 Philips Healthcare Business Overview
- 7.2.3 Philips Healthcare Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.2.4 Philips Healthcare Machine Learning in Respiratory Diseases Product Portfolio
- 7.2.5 Philips Healthcare Recent Developments
- 7.3 GE Healthcare
- 7.3.1 GE Healthcare Company Information
- 7.3.2 GE Healthcare Business Overview
- 7.3.3 GE Healthcare Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.3.4 GE Healthcare Machine Learning in Respiratory Diseases Product Portfolio
- 7.3.5 GE Healthcare Recent Developments
- 7.4 Siemens Healthineers
- 7.4.1 Siemens Healthineers Company Information
- 7.4.2 Siemens Healthineers Business Overview
- 7.4.3 Siemens Healthineers Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.4.4 Siemens Healthineers Machine Learning in Respiratory Diseases Product Portfolio
- 7.4.5 Siemens Healthineers Recent Developments
- 7.5 Swaasa AI
- 7.5.1 Swaasa AI Company Information
- 7.5.2 Swaasa AI Business Overview
- 7.5.3 Swaasa AI Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.5.4 Swaasa AI Machine Learning in Respiratory Diseases Product Portfolio
- 7.5.5 Swaasa AI Recent Developments
- 7.6 THIRONA
- 7.6.1 THIRONA Company Information
- 7.6.2 THIRONA Business Overview
- 7.6.3 THIRONA Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.6.4 THIRONA Machine Learning in Respiratory Diseases Product Portfolio
- 7.6.5 THIRONA Recent Developments
- 7.7 DeepMind Health
- 7.7.1 DeepMind Health Company Information
- 7.7.2 DeepMind Health Business Overview
- 7.7.3 DeepMind Health Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.7.4 DeepMind Health Machine Learning in Respiratory Diseases Product Portfolio
- 7.7.5 DeepMind Health Recent Developments
- 7.8 Verily
- 7.8.1 Verily Company Information
- 7.8.2 Verily Business Overview
- 7.8.3 Verily Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.8.4 Verily Machine Learning in Respiratory Diseases Product Portfolio
- 7.8.5 Verily Recent Developments
- 7.9 VIDA Diagnostics Inc
- 7.9.1 VIDA Diagnostics Inc Company Information
- 7.9.2 VIDA Diagnostics Inc Business Overview
- 7.9.3 VIDA Diagnostics Inc Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.9.4 VIDA Diagnostics Inc Machine Learning in Respiratory Diseases Product Portfolio
- 7.9.5 VIDA Diagnostics Inc Recent Developments
- 7.10 Icometrix
- 7.10.1 Icometrix Company Information
- 7.10.2 Icometrix Business Overview
- 7.10.3 Icometrix Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.10.4 Icometrix Machine Learning in Respiratory Diseases Product Portfolio
- 7.10.5 Icometrix Recent Developments
- 7.11 Infervision
- 7.11.1 Infervision Company Information
- 7.11.2 Infervision Business Overview
- 7.11.3 Infervision Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.11.4 Infervision Machine Learning in Respiratory Diseases Product Portfolio
- 7.11.5 Infervision Recent Developments
- 7.12 PneumoWave
- 7.12.1 PneumoWave Company Information
- 7.12.2 PneumoWave Business Overview
- 7.12.3 PneumoWave Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.12.4 PneumoWave Machine Learning in Respiratory Diseases Product Portfolio
- 7.12.5 PneumoWave Recent Developments
- 7.13 Respiray
- 7.13.1 Respiray Company Information
- 7.13.2 Respiray Business Overview
- 7.13.3 Respiray Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.13.4 Respiray Machine Learning in Respiratory Diseases Product Portfolio
- 7.13.5 Respiray Recent Developments
- 7.14 Dectrocel Healthcare
- 7.14.1 Dectrocel Healthcare Company Information
- 7.14.2 Dectrocel Healthcare Business Overview
- 7.14.3 Dectrocel Healthcare Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.14.4 Dectrocel Healthcare Machine Learning in Respiratory Diseases Product Portfolio
- 7.14.5 Dectrocel Healthcare Recent Developments
- 7.15 Zynnon
- 7.15.1 Zynnon Company Information
- 7.15.2 Zynnon Business Overview
- 7.15.3 Zynnon Machine Learning in Respiratory Diseases Revenue and Gross Margin (2021-2026)
- 7.15.4 Zynnon Machine Learning in Respiratory Diseases Product Portfolio
- 7.15.5 Zynnon Recent Developments
8 North America
- 8.1 North America Machine Learning in Respiratory Diseases Revenue (2021-2032)
- 8.2 North America Machine Learning in Respiratory Diseases Revenue by Type (2021-2032)
- 8.2.1 North America Machine Learning in Respiratory Diseases Revenue by Type (2021-2026)
- 8.2.2 North America Machine Learning in Respiratory Diseases Revenue by Type (2027-2032)
- 8.3 North America Machine Learning in Respiratory Diseases Revenue Share by Type (2021-2032)
- 8.4 North America Machine Learning in Respiratory Diseases Revenue by Application (2021-2032)
- 8.4.1 North America Machine Learning in Respiratory Diseases Revenue by Application (2021-2026)
- 8.4.2 North America Machine Learning in Respiratory Diseases Revenue by Application (2027-2032)
- 8.5 North America Machine Learning in Respiratory Diseases Revenue Share by Application (2021-2032)
- 8.6 North America Machine Learning in Respiratory Diseases Revenue by Country
- 8.6.1 North America Machine Learning in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Machine Learning in Respiratory Diseases Revenue by Country (2021-2026)
- 8.6.3 North America Machine Learning in Respiratory Diseases Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Machine Learning in Respiratory Diseases Revenue (2021-2032)
- 9.2 Europe Machine Learning in Respiratory Diseases Revenue by Type (2021-2032)
- 9.2.1 Europe Machine Learning in Respiratory Diseases Revenue by Type (2021-2026)
- 9.2.2 Europe Machine Learning in Respiratory Diseases Revenue by Type (2027-2032)
- 9.3 Europe Machine Learning in Respiratory Diseases Revenue Share by Type (2021-2032)
- 9.4 Europe Machine Learning in Respiratory Diseases Revenue by Application (2021-2032)
- 9.4.1 Europe Machine Learning in Respiratory Diseases Revenue by Application (2021-2026)
- 9.4.2 Europe Machine Learning in Respiratory Diseases Revenue by Application (2027-2032)
- 9.5 Europe Machine Learning in Respiratory Diseases Revenue Share by Application (2021-2032)
- 9.6 Europe Machine Learning in Respiratory Diseases Revenue by Country
- 9.6.1 Europe Machine Learning in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Machine Learning in Respiratory Diseases Revenue by Country (2021-2026)
- 9.6.3 Europe Machine Learning in Respiratory Diseases Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Machine Learning in Respiratory Diseases Revenue (2021-2032)
- 10.2 China Machine Learning in Respiratory Diseases Revenue by Type (2021-2032)
- 10.2.1 China Machine Learning in Respiratory Diseases Revenue by Type (2021-2026)
- 10.2.2 China Machine Learning in Respiratory Diseases Revenue by Type (2027-2032)
- 10.3 China Machine Learning in Respiratory Diseases Revenue Share by Type (2021-2032)
- 10.4 China Machine Learning in Respiratory Diseases Revenue by Application (2021-2032)
- 10.4.1 China Machine Learning in Respiratory Diseases Revenue by Application (2021-2026)
- 10.4.2 China Machine Learning in Respiratory Diseases Revenue by Application (2027-2032)
- 10.5 China Machine Learning in Respiratory Diseases Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Machine Learning in Respiratory Diseases Revenue (2021-2032)
- 11.2 Asia Machine Learning in Respiratory Diseases Revenue by Type (2021-2032)
- 11.2.1 Asia Machine Learning in Respiratory Diseases Revenue by Type (2021-2026)
- 11.2.2 Asia Machine Learning in Respiratory Diseases Revenue by Type (2027-2032)
- 11.3 Asia Machine Learning in Respiratory Diseases Revenue Share by Type (2021-2032)
- 11.4 Asia Machine Learning in Respiratory Diseases Revenue by Application (2021-2032)
- 11.4.1 Asia Machine Learning in Respiratory Diseases Revenue by Application (2021-2026)
- 11.4.2 Asia Machine Learning in Respiratory Diseases Revenue by Application (2027-2032)
- 11.5 Asia Machine Learning in Respiratory Diseases Revenue Share by Application (2021-2032)
- 11.6 Asia Machine Learning in Respiratory Diseases Revenue by Country
- 11.6.1 Asia Machine Learning in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Machine Learning in Respiratory Diseases Revenue by Country (2021-2026)
- 11.6.3 Asia Machine Learning in Respiratory Diseases Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Machine Learning in Respiratory Diseases Revenue (2021-2032)
- 12.2 SAMEA Machine Learning in Respiratory Diseases Revenue by Type (2021-2032)
- 12.2.1 SAMEA Machine Learning in Respiratory Diseases Revenue by Type (2021-2026)
- 12.2.2 SAMEA Machine Learning in Respiratory Diseases Revenue by Type (2027-2032)
- 12.3 SAMEA Machine Learning in Respiratory Diseases Revenue Share by Type (2021-2032)
- 12.4 SAMEA Machine Learning in Respiratory Diseases Revenue by Application (2021-2032)
- 12.4.1 SAMEA Machine Learning in Respiratory Diseases Revenue by Application (2021-2026)
- 12.4.2 SAMEA Machine Learning in Respiratory Diseases Revenue by Application (2027-2032)
- 12.5 SAMEA Machine Learning in Respiratory Diseases Revenue Share by Application (2021-2032)
- 12.6 SAMEA Machine Learning in Respiratory Diseases Revenue by Country
- 12.6.1 SAMEA Machine Learning in Respiratory Diseases Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Machine Learning in Respiratory Diseases Revenue by Country (2021-2026)
- 12.6.3 SAMEA Machine Learning in Respiratory Diseases Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst